Regeneron and Sanofi-Aventis announced that their experimental therapy aflibercept missed a mid-stage goal for an ovarian cancer trial. The primary goal was a five percent response for established criteria at two dosages. At the higher dose, researchers tracked a 4.5 percent response and a 0.9 percent response at the lower dose.
Aflibercept is also being tested in late-stage trials for prostate, colorectal, pancreatic and non-small cell lung cancers. Both companies say they're now evaluating how to proceed developing the therapy.
- take a look at the announcement
- read the AP story
Sanofi snags bigger stake, new pact with Regeneron
Sanofi, Regeneron launch late-stage cancer studies
Regeneron wins rich pact for VEGF trap